ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240104374758/en/
Website: https://renagadetx.com/
Contact
ReNAgade Therapeutics
Investor Relations
Argot Partners
Emily Brabbit
(212) 600-1902
renagade@argotpartners.com
Media Relations
Argot Partners
Sarah Sutton
(212) 600-1902
renagade@argotpartners.com
This news is a press release provided by ReNAgade Therapeutics.
-
2024년 4월 28일 11:40